Abstract：
UNASSIGNED: To develop turmeric extract-loaded chitosan microparticles for treating gastrointestinal disorders.
UNASSIGNED: The microparticles were prepared using a spray-drying process, optimised the characteristics by biomarker loading, and encapsulation efficiency, and assessed for bioactivities related to gastrointestinal diseases.
UNASSIGNED: The optimised microparticles were spherical, with a mean diameter of 2.11 ± 0.34 µm, a SPAN of 4.46 ± 0.68, a zeta potential of +37.6 ± 0.2 mV, loading of 15.7% w/w curcuminoids, 5.4% w/w ar-turmerone, and encapsulation efficiency of 63.26 ± 1.62% w/w curcuminoids and 43.75 ± 1.33% w/w ar-turmerone. Encapsulation of turmeric extract improved release at 6 h by 20 times and mucoadhesion by 3.6 times. The microparticles exhibited high acid-neutralising capacity (1.64 ± 0.34 mEq/g) and inhibited nitric oxide production about twice as effectively as the turmeric extract, while maintaining antioxidant and antibacterial activities.
UNASSIGNED: Encapsulation of turmeric extract in chitosan microparticles effectively enhanced therapeutic potential for gastrointestinal disorders.
UNASSIGNED: The microparticles were prepared using a spray-drying process, optimised the characteristics by biomarker loading, and encapsulation efficiency, and assessed for bioactivities related to gastrointestinal diseases.
UNASSIGNED: The optimised microparticles were spherical, with a mean diameter of 2.11 ± 0.34 µm, a SPAN of 4.46 ± 0.68, a zeta potential of +37.6 ± 0.2 mV, loading of 15.7% w/w curcuminoids, 5.4% w/w ar-turmerone, and encapsulation efficiency of 63.26 ± 1.62% w/w curcuminoids and 43.75 ± 1.33% w/w ar-turmerone. Encapsulation of turmeric extract improved release at 6 h by 20 times and mucoadhesion by 3.6 times. The microparticles exhibited high acid-neutralising capacity (1.64 ± 0.34 mEq/g) and inhibited nitric oxide production about twice as effectively as the turmeric extract, while maintaining antioxidant and antibacterial activities.
UNASSIGNED: Encapsulation of turmeric extract in chitosan microparticles effectively enhanced therapeutic potential for gastrointestinal disorders.
摘要：
■开发用于治疗胃肠道疾病的姜黄提取物负载的壳聚糖微粒。
■使用喷雾干燥工艺制备微粒，通过生物标志物加载优化了特征，和封装效率，并评估与胃肠道疾病相关的生物活性。
■优化的微粒是球形的，平均直径为2.11±0.34微米，跨度为4.46±0.68，ζ电位为+37.6±0.2mV，负载15.7%w/w姜黄素，5.4%w/war-turmerone,包封率63.26±1.62%w/w姜黄素和43.75±1.33%w/war-姜黄酮。姜黄提取物的胶囊在6小时时的释放提高了20倍，粘膜粘附提高了3.6倍。微粒显示出高酸中和能力（1.64±0.34mEq/g），并抑制一氧化氮的产生是姜黄提取物的两倍，同时保持抗氧化和抗菌活性。
■将姜黄提取物包封在壳聚糖微粒中有效地增强了对胃肠道疾病的治疗潜力。
■使用喷雾干燥工艺制备微粒，通过生物标志物加载优化了特征，和封装效率，并评估与胃肠道疾病相关的生物活性。
■优化的微粒是球形的，平均直径为2.11±0.34微米，跨度为4.46±0.68，ζ电位为+37.6±0.2mV，负载15.7%w/w姜黄素，5.4%w/war-turmerone,包封率63.26±1.62%w/w姜黄素和43.75±1.33%w/war-姜黄酮。姜黄提取物的胶囊在6小时时的释放提高了20倍，粘膜粘附提高了3.6倍。微粒显示出高酸中和能力（1.64±0.34mEq/g），并抑制一氧化氮的产生是姜黄提取物的两倍，同时保持抗氧化和抗菌活性。
■将姜黄提取物包封在壳聚糖微粒中有效地增强了对胃肠道疾病的治疗潜力。
